Fonte: Blood. Nome do evento: Annual Meeting and Exposition / ASH. Unidade: FM
Assuntos: LINFOMA (TERAPIA), FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO, SOBREVIDA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROBAK, Tadeusz et al. Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study. Blood. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://www.hematology.org/Annual-Meeting/Program/Education-Program.aspx. Acesso em: 08 set. 2024. , 2014APA
Robak, T., Huang, H., Jim, J., Shu, J., Liu, T., Samailova, O. S., et al. (2014). Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study. Blood. New York: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://www.hematology.org/Annual-Meeting/Program/Education-Program.aspxNLM
Robak T, Huang H, Jim J, Shu J, Liu T, Samailova OS, Pereira J, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov EA, Alexeeva J, Mayer J, Hong X, Maeda Y, Rooney B, van de Velde H, Cavalli F. Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study [Internet]. Blood. 2014 ; 124( 21):[citado 2024 set. 08 ] Available from: http://www.hematology.org/Annual-Meeting/Program/Education-Program.aspxVancouver
Robak T, Huang H, Jim J, Shu J, Liu T, Samailova OS, Pereira J, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov EA, Alexeeva J, Mayer J, Hong X, Maeda Y, Rooney B, van de Velde H, Cavalli F. Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study [Internet]. Blood. 2014 ; 124( 21):[citado 2024 set. 08 ] Available from: http://www.hematology.org/Annual-Meeting/Program/Education-Program.aspx